May 1, 2024 7:42am

A warning or suggestion to prepare for something literally or figuratively bumpy

News: the U.S. Fed’s latest interest rate announcement after the central bank’s monetary policy committee concludes a two-day meeting

Pre-open Indications: 1 Positive and 3 Negative Indications

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing money in your portfolio for the short and near-term

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RMi.

 

Wednesday: The pre-open Dow futures are DOWN -0.21% or (-78 points), the S&P futures are DOWN -0.36% or (-18 points) as the Nasdaq futures are DOWN -0.59% or (-104 points)

Futures fall bracing for Fed rate decision; Wednesday, 2/1,

London’s FTSE 100 index was slightly higher,

Asia pacific markets were mixed as Japanese and Austrian markets fell.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Tuesday: The Dow closed DOWN -570.24 points or -1.49%, the S&P closed DOWN -80.48 points or -1.57% while the Nasdaq closed DOWN -325.26 points or -2.04%

Diving in the month of April, the Dow (-4.3%), the S&P 500 (-3%) and Nasdaq (-3%) declined.

Traders are now looking toward the Fed’s interest rate decision on Wednesday afternoon.

Economic Data Docket:

  • JOLTS job openings, March (8.72 million expected, 8.76million last month);
  • S&P Global US Manufacturing PMI, April final (49.9 expected, 49.9 previously);
  • ISM Manufacturing, April (50.1expected, 50.3 previously); ISM prices paid, April (55.8 previously);
  • Construction spending month-over-month, Mach (+0.3% expected, -0.3% previously):
  • Federal Open Market Committee rate decision (no change expected)

 

Tuesday night’s RegMed Investors (RMi) Closing Bell: “ending April on a sour note. The cell and gene therapy sector traded into the red Tuesday after higher-than-expected wage data raised fresh inflation concerns.” … https://www.regmedinvestors.com/articles/13440

 

Q2/24:  May - 1st session

  • April - 16 negative and 6 positive closes

Q1/24:

  • March – 8 positive and 12 negative closes
  • February – 1 market holiday, 11 positive and 9 negative closes
  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

Negative Indication:

Tuesday, Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Sage Therapeutics (SAGE) closed down -$0.24 after Monday’s +$0.49 and Friday’s +$0.11 with a neutral pre-open indication

 

Positive Indication:

Tuesday, Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Ionis Pharmaceuticals (IONS -$0.73, Monday’s +$0.40, Friday’s -$0.25, Thursday’s -$0.61 and last Wednesday’s +$0.61 post the previous Tuesday’s +$0.77 and Monday’s +$0.39 with a positive +$0.03 or+0.07% pre-open indication.

Mesoblast (MESO) closed down -$0.50 with a positive +$0.27 or +4.09% pre-open indication.

Regenxbio (RGNX) closed down -$0.70 after Monday’s +$0.14, Thursday’s +$0.02 and last Wednesday’s +$0.14 with a neutral pre-open indication.

 

The BOTTOM LINE:  Don’t base your portfolio on this statement, “The old saying, "Sell in May and go away" is not just folklore — stock market history supports it.”

History shows stock market performance tends to sag from May to October compared with the November-April period. Still, investors can expect low single-digit gains over the next six months.

  • But the results have been less dramatic in the last 10 years, with the November-April period gaining 5.5% vs. a 4% increase the other six months. And the gap has widened slightly over the last five years, to 6% vs. 4%, according to Dow Jones Market Data. <IBD>

Yet, I can’t my hands around this statement – uncertainty begets anxiety yet, hope springs eternal and … bias outcomes!

 

“I hate to be negative or contrarian but, this is a NO spin zone and pricing truth is its product; I can always be WRONG but, I am mostly EARLY!”

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct business school (MBA) professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and just about … everything.

Also, as a quantamental “plotter” I equate myself to a quantitative analyst straddling fundamental stock picking to produce better results for investors. the term “quantamental,” blends the two styles setting forth my difference retail, trading and multiple investor categories.

 

The cell and gene therapy sector is still in play as earning season comes with a full wind…

  • While on Friday, the cell and gene therapy sector erased gains closing positive on Friday, closing down on Thursday, Wednesday after positive closes on Tuesday and Monday.

 

Q1/24 Reporting Season:

  • Alnylam Pharmaceuticals (ALNY), Ultragenyx Pharmaceuticals (RARE), AxoGen (AXGN), Blueprint Medicine (BPMC) on Thursday, 5/2;
  • Ionis Pharmaceuticals (IONS) and Agenus (AGEN) on Tuesday, 5/7,
  • Vericel (VCEL), Regenxbio (RGNX) on Wednesday, 5/8
  • BioLife Solutions (BLFS) on Thursday, 5/9

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.